Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Sex Workers, MSM, and Transgender Persons: Disruption in access to PrEP services, reduced capacity for HIV prevention services, , reduced availability of HIV counselling and testing, and disruption in ...

A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...